Background: The management of Philadelphia Chromosome-positive (Ph+) hematological
malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the BCR-
ABL oncoprotein, known to drive leukemogenesis by orchestrating multiple signaling …

Abstract Purpose: Leukemic stem cells (LSCs) may harbor important resistance to tyrosine
kinase inhibitors in chronic myelogenous leukemia (CML). We identified Philadelphia …

Background Chronic myeloid leukemia (CML) is a common hematological malignancy, and
tyrosine kinase inhibitors (TKIs) represent the primary therapeutic approach for CML …

Introduction: As survival of patients with chronic myeloid leukemia (CML) is dramatically
improved over time, the prevalence of the disease is steadily increasing. At this moment, five …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t (9;
22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor …

The clinical outcome for patients with chronic myeloid leukemia (CML) has improved
significantly with the introduction of tyrosine kinase inhibitors (TKIs). However, their curative …

Tumor suppressor function can be modulated by subtle variation of expression levels,
proper cellular compartmentalization and post-translational modifications, such as …

We recently described morgana as an essential protein able to regulate centrosome
duplication and genomic stability, by inhibiting ROCK. Here we show that morgana+/− mice …

Although tyrosine kinase inhibitors (TKIs) have dramatically improved clinical outcome in
chronic myeloid leukemia (CML), cure rarely occurs. This may be due to BCR-ABL …